CDK4 and breast carcinoma: Network meta-analysis (NMA) evidence has partially covered CDK4/6 inhibitors in treatment-naïve HR + breast cancer patients, and the results show that adding CDK4/6 inhibitors to endocrine therapy is an effective choice (Liu et al., 2023; Guo et al., 2024; Kappel et al., 2024).